WASHINGTON (dpa-AFX) - Cell Therapeutics, Inc. or CTI (CTIC) announced results from sub-set analyses of data from the Phase 3 EXTEND, or PIX301, study of PIXUVRI. The analyses assessed the efficacy of PIXUVRI in the subset of patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma or NHL, as confirmed by central independent pathological review, who had failed 2 or 3 prior treatment regimens.
The single agent PIXUVRI resulted in 30 percent of patients who had earlier received rituximab achieving a complete or unconfirmed durable complete response lasting on average 9.5 months with 67 percent of patients surviving at 2 years, compared with physicians' choice of other agents given as monotherapy. In contrast, only 5.6 percent of patients in the comparator arm achieved an unconfirmed complete response. The benefit of PIXUVRI has not be established in patients when used as 5th-line or greater chemotherapy.
'PIXUVRI is the first medicinal product approved in the E.U. for treatment of patients with aggressive B-cell NHL,' said Ruth Pettengell, M.D., of St. George's Hospital, University of London, the lead investigator for the EXTEND trial. Pettengell continued, 'These subset analyses support PIXUVRI's use and benefit as a 3rd and 4th line treatment, whether or not the patient was previously exposed to rituximab. Prior to PIXUVRI, treatment options were limited to palliative therapy or clinical trials. PIXUVRI may provide the ability to re-introduce effective salvage therapy even after patients fail standard aggressive second line treatment.'
Copyright RTT News/dpa-AFX
© 2013 AFX News
